These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 20655243)

  • 1. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.
    Barthélémy P; Heitz D; Mathelin C; Polesi H; Asmane I; Litique V; Rob L; Bergerat JP; Kurtz JE
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):196-204. PubMed ID: 20655243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution.
    Kurtz JE; Heitz D; Serra S; Brigand C; Juif V; Podelski V; Meyer P; Litique V; Bergerat JP; Rohr S; Dufour P
    Crit Rev Oncol Hematol; 2010 Jun; 74(3):211-7. PubMed ID: 19560368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients.
    DeMichele A; Putt M; Zhang Y; Glick JH; Norman S
    Cancer; 2003 May; 97(9):2150-9. PubMed ID: 12712466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer in elderly women: outcome as affected by age, tumor features, comorbidities, and treatment approach.
    Siegelmann-Danieli N; Khandelwal V; Wood GC; Mainali R; Prichard J; Murphy TJ; Evans JF; Yumen O; Bernath AM
    Clin Breast Cancer; 2006 Apr; 7(1):59-66. PubMed ID: 16764745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.
    Kuo SH; Lien HC; You SL; Lu YS; Lin CH; Chen TZ; Huang CS
    Breast; 2008 Dec; 17(6):646-53. PubMed ID: 18595699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients.
    Bastiaannet E; Liefers GJ; de Craen AJ; Kuppen PJ; van de Water W; Portielje JE; van der Geest LG; Janssen-Heijnen ML; Dekkers OM; van de Velde CJ; Westendorp RG
    Breast Cancer Res Treat; 2010 Dec; 124(3):801-7. PubMed ID: 20428937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
    Lohrisch C; Paltiel C; Gelmon K; Speers C; Taylor S; Barnett J; Olivotto IA
    J Clin Oncol; 2006 Oct; 24(30):4888-94. PubMed ID: 17015884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of operable invasive breast cancer in women over the age of 70: long-term results of a large-scale single-institution experience.
    Laki F; Kirova YM; Savignoni A; Campana F; Levu B; Estève M; Sigal-Zafrani B; Dorval T; Asselain B; Salmon RJ
    Ann Surg Oncol; 2010 Jun; 17(6):1530-8. PubMed ID: 20177798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
    Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
    Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer treatment guidelines in older women.
    Giordano SH; Hortobagyi GN; Kau SW; Theriault RL; Bondy ML
    J Clin Oncol; 2005 Feb; 23(4):783-91. PubMed ID: 15681522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
    Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
    Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
    Jara Sánchez C; Ruiz A; Martín M; Antón A; Munárriz B; Plazaola A; Schneider J; Martínez del Prado P; Alba E; Fernández-Aramburo A
    Breast Cancer Res Treat; 2007 Jan; 101(2):215-23. PubMed ID: 16823507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands.
    Sukel MP; van de Poll-Franse LV; Nieuwenhuijzen GA; Vreugdenhil G; Herings RM; Coebergh JW; Voogd AC
    Eur J Cancer; 2008 Sep; 44(13):1846-54. PubMed ID: 18640030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.